Is Aurobindo Pharma (AUROPHARMA) overvalued or fairly valued?

MarketChacha shows Aurobindo Pharma's valuation in context — a forward P/E of about 17.4, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Aurobindo Pharma's revenue?

Aurobindo Pharma reported revenue of ₹33,653 Cr for FY2026, with net profit of ₹3,505 Cr, per official filings.

What is the share price of Aurobindo Pharma (AUROPHARMA)?

Aurobindo Pharma last traded at ₹1,621.40 (-3.4% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Aurobindo Pharma

AUROPHARMA · NSE · Pharma · India

Snapshot

TickerAUROPHARMA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees29,209

HeadquartersHyderabad, India

Websitewww.aurobindo.com

Filings tracked10

About Aurobindo Pharma

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Who owns it

Promoters54.8%
Institutions29.3%
Public & other16.0%

199 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend7.8% → 10.4%

Margin has expanded by about 2.7 points — the business is getting more profitable.

Growth qualityrev 11% · PAT 22%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹10,297 Cr · EPS 21.31

Est. earnings growth +29.7%

Next fiscal year

Rev ₹44,442 Cr · EPS 93.43

Est. earnings growth +16.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹33,653 Cr

Net margin

10.4%

Revenue CAGR (3y)

+10.6%

Profit CAGR (3y)

+22.1%

Net profit (FY2026)

₹3,505 Cr

Ask MarketChacha about AUROPHARMA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹33,653 Cr	₹3,505 Cr	10.4%
FY2025	₹31,724 Cr	₹3,486 Cr	11.0%
FY2024	₹29,002 Cr	₹3,173 Cr	10.9%
FY2023	₹24,855 Cr	₹1,928 Cr	7.8%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹9,150 Cr	₹1,033 Cr	11.3%
Q4 FY26	₹8,853 Cr	₹921 Cr	10.4%
Q3 FY26	₹8,646 Cr	₹910 Cr	10.5%
Q2 FY26	₹8,286 Cr	₹848 Cr	10.2%
Q1 FY26	₹7,868 Cr	₹825 Cr	10.5%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Completion Of US FDA Inspection At Unit-II Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
Submission of completion of US FDA inspection of Unit-II of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.
BSE9/15/2026
Press Release / Media Release
Submission of Press Release that is being issued in connection with receipt of US FDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol , 40 mcg and 80 mcg.
BSE9/15/2026
Press Release / Media Release (Revised)
Submission of Press Release.
BSE8/31/2026
Press Release / Media Release
Submission of Press Release on financial results of the Company for the first quarter ended June 30, 2026.
BSE8/5/2026
Investor Presentation
Submission of investor presentation.
BSE8/5/2026
Board Meeting Outcome for Outcome Of The Board Meeting Held On August 5, 2026
The Board of Directors of the Company at its meeting held today, August 5, 2026, has, inter alia, considered and approved: a) the standalone and consolidated Unaudited Financial Results ....
BSE8/5/2026
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Confirmation of dispatch of letter to the shareholders who have not registered their email ids, providing weblink for integrated Annual Report 2025-26.
BSE8/4/2026
Business Responsibility and Sustainability Reporting (BRSR)
Submission of BRSR for FY 2025-26.
BSE8/3/2026
Reg. 34 (1) Annual Report.
Submission of Integrated Annual Report 2025-26
BSE8/3/2026
Press Release / Media Release
Submission of press release that is being issued in connection with signing non exclusive voluntary license agreement with MSD.
BSE7/24/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.